近些年来,TP53 突变与血液系统疾病的相关性研究逐渐成为热点,不论在淋巴瘤还是在白血病中,伴随 TP53 突变均提示高风险或预后不良,有效且高质量的移植对患者至关重要[3]。 131I-apamistamab 引导的 HCT 显著改善了伴 TP53 突变的 R/R ...
在 ELN 2017 不良风险类别的背景下,TP53突变型与生存率降低密切相关(2年OS率,12.8%TP53突变型 vs. 42.5%TP53野生型;P< 0.001)(1A)。由于TP53突变型AML 和 MDS-EB 的分子同质性,研究人员探索了 AML 或 MDS-EB 状态是否与生存相关,结果显示...
Decitabine in TP53-mutated AML. N Engl J Med 2017; 376(8): 797-798 (Correspondence)Montalban-Bravo G, Takahashi K, Garcia-Manero G. Decitabine in TP53-mutated AML. N Engl J Med 2017; 376(8): 796-798 (Correspondence)Montalban-Bravo, G.; Takahashi, K.; Garcia-Maneiro, G. Decitabine...
除了在美国和加拿大的医院外,玛丽医院的血液科将成为参与全球临床试验的治疗地点,以测试PLK4抑制剂对AML患者的影响。 Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML
吉瑞替尼,一种靶向治疗急性髓系白血病(AML)的创新药物,一般用于治疗采用经充分验证的检测方法检测到携带FMS样酪氨酸激酶3(FLT3)突变的复发性或难治性急性髓系白血病(AML)成人患者,近年来在临床试验中展现出了令人瞩目的疗效。 急性髓系白血病(AML)的发生和进展与多种基因突变密切相关,包括FLT3、NPM1、CEBPA、TP53等...
基因数据现在被使用于患者的疾病分类、风险分层和临床治疗。Two new provisional entities, AML with mutated RUNX1 and AML with BCR-ABL1, have been included in the current update of the WHO classification of myeloid neoplasms and AML, and mutations in three genes—RUNX1, ASXL1, and TP53—have ...
novel, first-in-class small molecule that selectively induces apoptosis in TP53 mutated cancer cells via thermodynamic stabilization of the TP53 protein and shifting the equilibrium toward the wild-type conformation with restoration of the transcriptional activity of unfolded wild-type or mutant TP53 [...
(Fig.1f, g). There was no benefit in using the combination treatment on theTP53mutated cell lines (Fig.1h–j) (CI for all mutantTP53lines > 1). To confirm these results we also calculated drug synergy by the Bliss method27. This also showed substantially greater and more consistent ...
TP53-mutated myelodysplastic syn- Transplant. 2010;16:413–20. drome and acute myeloid leukemia: biology, cur- Barba P, Martino R, Perez-Simon JA, et al. Combination rent therapy, and future directions. Cancer Discov. of the hematopoietic cell transplantation comorbidity 2022;12(11):2516–...
We’ve seen in MDS that magrolimab and azacitidine seems to lead to similar CR rates for patients with TP53-mutated disease and those who don’t have TP53-mutated disease. There is some excitement that this may be a benefit to those very high-risk patients. The other promising therapy is...